Back to News
Market Impact: 0.18
Augurex Announces Mayo Clinic Laboratories Now Offering 14-3-3eta Testing for Rheumatoid Arthritis
Source: Business Wire
Healthcare & BiotechProduct Launches
Mayo Clinic Laboratories now offers Augurex's 14-3-3eta serum test, a rheumatoid arthritis biomarker designed to complement RF and anti-CCP testing. The expanded availability could support earlier RA diagnosis, representing a modest positive commercial and clinical-validation milestone for Augurex.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Beta Bionics prices $150M public offering at $17.25/share
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- SpaceX will try to put Starship in orbit for the first time on September 22
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- SpaceX’s Starship is finally set for orbit. A lot is riding on its success.